Common Stock, $0.001 Par Value Per Share
- Symbol
- DXCM
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 8.01, 9.01 · 8-K
DexCom, Inc.
DXCMNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Other Events
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 29, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report.…
Press release in this filing
Dexcom Reports Third Quarter 2026 Financial Results →Registered securities in this filing
DEXCOM, INC. · 8-K · Filed 2026-10-29
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On October 29, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
ITEM 8.01. OTHER EVENTS.
On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than December 31, 2027 (the “Share Repurchase Program”).
Repurchases of Common Stock under the Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, at Dexcom’s discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at Dexcom’s discretion.
The Share Repurchase Program does not obligate Dexcom to repurchase any dollar amount or number of shares of Common Stock, and the program may be extended, modified, suspended, or discontinued at any time.